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Drug-resistant tuberculosis (DR-TB), especially TB resistant to 
rifampicin (RIF, RR-TB), threatens global TB control and is a major 
public health concern. In 2014, there were an estimated 480 000 
new cases of multidrug-resistant TB (MDR-TB) worldwide, and 
an estimated 190 000 people died from MDR-TB.[1] In 2014, South 
Africa (SA) initiated 11 538 patients with RR-TB, including MDR-
TB, on second-line TB treatment. Of the 2012 cohort of RR-TB 
cases, only 52% had a reported treatment outcome, the remainder 
having no outcome information reported. Among the patients with 
outcomes, the RR-TB treatment success rate was 49%.
DR-TB cases are classified into the following categories, based 
on drug susceptibility testing: (i) monoresistance (resistance to one 
first-line anti-TB drug only); (ii) polydrug resistance (resistance to 
more than one first-line anti-TB drug, other than both isoniazid 
(INH) and RIF); (iii) MDR-TB (resistance to both INH and RIF); 
and (iv) extensive drug resistance (XDR-TB, resistance to any 
fluoroquinolone and at least one second-line injectable drug in 
addition to MDR-TB). RR-TB, defined as RIF resistance with or 
without resistance to other anti-TB drugs, includes monoresistant 
TB, MDR-TB and XDR-TB.
A review of cases reported to the national electronic register of 
drug-resistant TB (EDRweb) from 2009 to 2011 found that 29.5% 
of RR-TB patients were reported as lost from treatment.[2] Other 
studies conducted in SA have reported rates of loss to follow-up in 
patients on treatment for MDR-TB of 20 - 30%.[3-5] Associated risk 
factors include male gender, HIV co-infection,[3,5] young age, previous 
RR-TB treatment,[5] substance abuse and the attitude of healthcare 
workers.[6]
With the implementation of outpatient (ambulatory) decentralised 
RR-TB treatment in SA since late 2011, the potential for RR-TB 
patients to miss appointments is a concern. RR-TB patients who 
miss appointments may not have been able to visit the clinic because 
of TB morbidity or mortality or adverse drug events, but clinicians 
are not able to intervene if the patient is not in the clinic. Missed 
appointments also lead to treatment interruptions contributing to 
amplification of resistance, ongoing transmission of RR-TB, and an 
increased risk of morbidity and mortality.[7]
Objective
To describe the occurrence of missed appointments during decen-
tralised outpatient RR-TB treatment, in order to inform strategies to 
reduce loss to follow-up, treatment failure and death.
Methods
Study site and standard of care
The study was conducted at a decentralised RR-TB outpatient clinic 
at Helen Joseph Hospital (HJH) in Johannesburg, SA.
With full-scale roll-out of GeneXpert MTB/RIF at the end of 
2013, all individuals with presumptive TB in the SA public sector 
are also tested for RIF resistance. Those who are GeneXpert-
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Background. With the implementation of outpatient (ambulatory) decentralised rifampicin-resistant tuberculosis (RR-TB) treatment in 
South Africa (SA) since late 2011, the high rates of loss from treatment are a significant concern. Missed appointments lead to treatment 
interruptions and may contribute to amplification of resistance, ongoing transmission of RR-TB and an increased risk of morbidity and 
mortality to the patient.
Objective. To describe characteristics of patients who missed scheduled appointments during ambulatory RR-TB treatment.
Methods. The study was a retrospective, deidentified electronic medical record review of RR-TB patients at an outpatient clinic in 
Johannesburg, SA, from March 2013 to December 2014. Associations between missed appointments and clinical and demographic 
characteristics were analysed using time-to-event Cox proportional hazards regression.
Results. Of 172 patients who met the eligibility criteria, 53.5% missed at least one appointment and 39.5% missed three or more. More than 
half (59.8%) of first missed appointments occurred within the first 3 months after treatment initiation. The median number of days from 
initiation until the first missed appointment was 82 (interquartile range 52 - 260.5). HIV-infected patients with a CD4 count of ≤100 cells/
µL (adjusted hazard ratio (aHR) 4.25, 95% confidence interval (CI) 1.49 - 12.18), patients referred from an inpatient facility (aHR 1.96, 95% 
CI 1.18 - 3.25) and patients aged 18 - 24 years as opposed to those aged 35 - 44 years (aHR 3.26, 95% CI 1.20 - 8.84) were all more likely to 
miss one or more appointments.
Conclusion. HIV-infected patients with a low CD4 count, patients referred from inpatient care and young patients are at high risk of 
missing appointments and should receive interventions targeted at improving retention.
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negative but with symptoms indicative of TB may have additional 
smear microscopy or culture. Patients with a diagnosis of RR-TB 
are referred to the HJH RR-TB clinic on discharge from inpatient 
care or from other outpatient facilities for initiation of second-line 
TB treatment.
The SA National Department of Health has implemented a DR-TB 
management programme since early 2000 through the National 
TB Control Programme (NTCP). The NTCP guidelines up to 
2011 stipulated that all MDR-TB patients should be hospitalised 
for 6 months or until sputum culture conversion (two consecutive 
negative cultures taken 1 month apart). The 2011 NTCP guidelines 
indicate that all smear microscopy-negative, culture-positive MDR-
TB patients should be started on ambulatory (outpatient) treatment; 
smear-positive MDR-TB patients should be hospitalised until smear 
conversion (two consecutive negative sputum smears); and non-
ambulatory MDR-TB and XDR-TB patients should be hospitalised 
until culture conversion.[8]
The NTCP treatment guidelines indicate that patients with 
RR-TB should be initiated on a standardised regimen for MDR-TB 
while further test results on drug resistance are pending.[9] The 
standardised regimen has an intensive phase of 6 months, during 
which patients are treated with a second-line injectable (kanamycin 
or amikacin) and fluoroquinolone (moxifloxacin), plus terizidone, 
ethionamide and pyrazinamide. The continuation phase can vary 
in length, but should be at least 18 months following culture 
conversion and includes moxifloxacin, terizidone, ethionamide 
and pyrazinamide. Regimens can be individualised once there 
is evidence of either additional resistance (e.g. pre XDR-TB) or 
adverse reactions to the standardised regimen. Clinicians can 
add high-dose INH if there is an indication that it may still be an 
effective drug.
In SA, all HIV-infected TB patients, regardless of the level of TB 
drug resistance or CD4 count, are eligible for immediate initiation 
of antiretroviral (ARV) therapy.[10] HIV care is integrated with the 
RR-TB treatment; treatment and adverse event monitoring, including 
ARV pill collection, are provided for RR-TB and HIV co-infected 
patients at the HJH RR-TB clinic to reduce the number of clinic visits 
and improve adherence.
Patients enrolled for RR-TB management are given a scheduled 
appointment date to return to the HJH RR-TB clinic 2 weeks after 
RR-TB treatment initiation and then every 4 weeks (monthly) for 
18 - 24 months. Patients can attend the clinic on any weekday during 
clinic hours at any point for an unscheduled appointment if they are 
feeling unwell. The patient can choose whether they want to attend 
the HJH RR-TB clinic or an alternative primary healthcare clinic 
closer to their home for daily directly observed treatment support 
and injections during the intensive phase. The treating clinician at 
the HJH RR-TB clinic retains responsibility for patient management 
throughout the 18 - 24 months of treatment.
Study design
The study was a retrospective, deidentified electronic medical 
record review. The site maintains electronic records of patients on 
a dedicated Microsoft Access database (2007 version, Microsoft, 
USA). For the study, a census of all patients enrolled in care at 
the site with documented RIF resistance between 1 March 2013 
and 31  December 2014 was extracted. Follow-up data on visits to 
determine appointments missed and outcomes (treatment com-
pleted, died, lost from treatment) were extracted until the data 
extraction (28 February 2015), 18 months of treatment, death or loss 
to follow-up (defined as treatment interruption for 2 consecutive 
months[11]), whichever came earliest. Patients <18 years of age, those 
with INH monoresistant TB and those who were transferred to 
another treatment site were excluded from the analysis.
A missed appointment was defined as a monthly (4-weekly) 
appointment date scheduled by the clinic for which the patient did 
not have an actual appointment date recorded. The electronic medical 
record used at every patient visit has a data field where the next 
scheduled appointment date is captured, and it also has an adjacent 
data field where the actual appointment date on which the patient 
attended the clinic is captured. Scheduled appointment dates were 
set by the clinic staff during routine implementation and not through 
this analysis. Revised appointment dates to ‘catch up’ for previously 
delayed appointments or decisions as to whether an appointment was 
3 weeks late or 1 week early after a missed appointment were made by 
the clinic staff as part of routine care.
Statistical analysis
Patients were categorised as having missed one or more appointments 
or no missed appointment. Associations between ever missing an 
appointment and clinical characteristics were analysed using time-
to-event Cox proportional hazards regression. Clinical characteristics 
included HIV infection, CD4 count ≤100 cells/µL or >100 cells/
µL if HIV-infected, diagnosed at and referred from an outpatient or 
inpatient facility, any cough at RR-TB treatment initiation, pulmonary 
or extrapulmonary TB foci, resistance to RIF only or MDR-TB, and 
sputum smear microscopy-positive at initiation. Socioeconomic and 
demographic characteristics analysed included gender, age categories 
(18 - 24, 25 - 34, 35 - 44, 45 - 54 and ≥55 years), employed or unemployed, 
SA or foreign national, primary, secondary or tertiary education, and 
living with children aged ≤5 years. Hazard ratios adjusted for the other 
clinical and demographic characteristics (aHRs) were presented 
with 95% confidence intervals (CIs). Statistical significance was set at 
p<0.05. All analysis was done using Stata version 13.1 (StataCorp, USA).
Ethics approval
Ethics approval for the study was received from the Human Research 
Ethics Committee of the University of the Witwatersrand (Ref. no. 
M150341), and permission to conduct the research was obtained from 
HJH. The study site routinely requests patients to provide informed 
consent for record review. Patients who declined or withdrew informed 
consent for review of medical records were excluded.
Results
Patient characteristics
During the study period, 172 patients who were initiated on RR-TB 
treatment at the study site from March 2013 to December 2014 
met the eligibility criteria and were included in the analysis. The 
median age of patients initiated on RR-TB treatment was 36 years 
(interquartile range (IQR) 29 - 42), and 49.4% were male (Table 1). 
Most patients (80.8%) had a secondary school education, and 6.4% 
had a tertiary-level education. The majority of patients (83.7%) were 
SA citizens, and 43.6% were employed.
HIV status was known for 169 patients (98.3%); 148 (86.0%) were 
HIV-infected, with a median CD4 count of 85 cells/µL (IQR  26 - 
195). Of the HIV-infected patients, 90 (60.8%) were on ART, with 
61/148 patients (41.2%) having been on ART for ≥6 months at 
initiation of RR-TB treatment.
Nearly half the patients (n=79, 45.9%) were referred from inpatient 
care, i.e. they had recently been hospitalised for their condition. 
The majority of patients (90.1%) had pulmonary TB. Most patients 
(70.3%) were smear microscopy-negative or smear results were 
missing at initiation of second-line TB treatment. The median weight 
was 51 kg (IQR 45.1 - 59.3).
TB history was reported for 170 patients, with 103 (60.0%) 
reporting no previous history of TB treatment, 53 (30.8%) reporting 
a history of previous first-line TB treatment and 14 (8.1%) reporting 
a history of receiving a TB regimen that included streptomycin.
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Missed appointments and treatment outcomes
The study found that 53.5% of patients (n=92) missed at 
least one appointment; 39.5% (n=68) missed at least three 
appointments. Nineteen patients (11.0%) died during the study 
period, 38  (22.1%) were lost to follow-up, and 115 (66.9%) 
had either completed treatment or remained on treatment at 
18 months (Table 2). All 80  patients who had not missed an 
appointment had an outcome of either treatment completed or 
remaining on treatment at 18 months. Of the 92 patients who had 
missed one or more appointment, 19 (20.7%) died, 38 (41.3%) 
were lost from treatment and 35 (38.0%) completed treatment or 
remained on treatment at 18 months.
Time to missed appointments
A total of 37 940 person-days were analysed, and on average each 
patient contributed 221 days to the analysis. The time at risk of 
missed appointments was censored at 540 days (18 months). More 
than half (59.8%) of all first missed appointments occurred in first 
3 months of treatment (Fig. 1). The median number of days from 
Table 1. Patient clinical and demographic characteristics at 
initiation of second-line TB treatment (N=172)*
Description n (%)
HIV status
Positive 148 (86.0)
Negative 21 (12.2)
CD4 count (cells/µL)
<101 67 (48.6)
>100 55 (39.9)
Antiretroviral status
On ART at RR-TB treatment initiation 90 (60.8)
Not on ART at initiation 58 (39.2)
Antiretroviral history
Not on ART or on ART <6 mo at initiation 69 (53.1)
On ART ≥6 mo at initiation 61 (46.9)
Referring site
Outpatient facility 86 (50.0)
Inpatient facility 79 (45.9)
TB symptoms
Any cough at initiation 118 (68.6)
No cough or no report of cough 54 (31.4)
Site of TB
Pulmonary 155 (90.1)
Extrapulmonary 17 (9.9)
Smear status
Microscopy positive 51 (29.7)
Microscopy negative or not reported 121 (70.3)
Resistance
MDR-TB (resistant to INH and rifampicin) 38 (22.1)
RIF monoresistant TB 82 (47.7)
RIF resistant by GeneXpert MTB/RIF 52 (30.2)
TB history
No previous TB treatment reported 103 (59.9)
Previous first-line TB treatment 53 (30.8)
Previous retreatment TB regimen (streptomycin) 14 (8.1)
Weight at initiation (kg)
<55 74 (43.0)
>54 89 (51.7)
Continued ...
Table 1. (continued) Patient clinical and demographic 
characteristics at initiation of second-line TB treatment 
(N=172)*
Description n (%)
Gender
Male 85 (49.4)
Female 87 (50.6)
Age (years)
18 - 24 14 (8.1)
25 - 34 51 (29.7)
35 - 44 74 (43.0)
45 - 54 24 (14.0)
≥55 9 (5.2)
Education
Primary 22 (12.8)
Secondary 139 (80.8)
Tertiary 11 (6.4)
Citizenship
SA 144 (83.7)
Non-SA 28 (16.3)
Employment
Not employed or only day labour 95 (55.2)
Employed or self-employed 75 (43.6)
Children
Children aged ≤5 years at home 100 (58.1)
No children aged ≤5 years at home 64 (37.2)
Not reported 8 (4.7)
*Patients with missing data were excluded from the relevant analysis: HIV status n=3, 1.7%; 
CD4 count if HIV-positive n=16, 11.6%; referring site n=7, 4.1%; TB history n=2, 1.2%; 
weight n=9, 5.2%; employment status n=2, 1.2%.
Table 2. Missed appointments and treatment outcome at 18 months or data extraction
Treatment outcome
No missed appointments,
n (%)
Missed ≥1 appointment/s,
n (%)
Missed ≥3 appointments,
n (%)
Total,
n (%)
On treatment or treatment completed 80 (100.0) 35 (38.0) 21 (30.9) 115 (66.9)
Died 0 (0) 19 (20.7) 9 (13.2) 19 (11.0)
Lost from treatment 0 (0) 38 (41.3) 38 (55.9) 38 (22.1)
Total 80 (46.5) 92 (53.5) 68 (39.5) 172 (100.0)
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treatment initiation until the first missed 
appointment was 82 days (IQR 52 - 260.5). 
The Kaplan-Meier curve demonstrated 
that missed appointments occurred earlier 
among patients who had an outcome of loss 
from treatment or death than among those 
who had an outcome of treatment completed 
or remaining on treatment at 18  months 
(Fig. 2). Missed appointments also occurred 
earlier after treatment initiation among 
patients referred from inpatient care than 
among those referred from outpatient 
facilities (Fig. 3).
Predictors of missed appointments
Adjusted Cox proportional hazards reg ression 
analysis demon strated that HIV-infected 
patients with a CD4 count of ≤100  cells/
µL were 4.25 times more like ly to miss an 
appointment than those with a CD4 count of 
>100 cells/µL (95% CI 1.49 - 12.18) (Table 3). 
Patients aged 18 - 24 years were at a three 
times higher risk of missing an appointment 
compared with those aged 35 - 44 years 
(aHR 3.26, 95% CI 1.20 - 8.84); patients 
aged 25 - 34 years were also at increased 
risk (aHR 1.94, 95% CI 1.10 - 3.44). Patients 
who were referred from inpatient facilities 
were twice as likely to miss an appointment 
as those who were referred from outpatient 
facili ties (aHR 1.96, 95% CI 1.18 - 3.25). 
When the site of TB was pulmonary, patients 
were almost three times more likely to miss 
an appointment compared with patients 
who had an extrapulmonary site of TB 
(aHR  2.77, 95% CI 1.04 - 7.34). Although 
not statistically significant, patients with a 
tertiary-level education were less likely to 
miss an appointment than patients with a 
primary school education (aHR 0.28, 95% CI 
0.07 - 1.07).
Discussion
The finding that 53.5% of patients missed 
one or more appointments during outpatient 
treatment for RR-TB is of concern. Patients 
referred from inpatient care, HIV-infected 
patients with a CD4 count ≤100 cells/µL 
and young patients (18 - 24 years) are at a 
significantly increased risk of missing an 
appointment. Missing at least one scheduled 
appointment at the RR-TB clinic was strongly 
associated with poor treatment outcomes; 
patients missing three or more appointments 
were even less likely to complete treatment 
successfully.
The proportion of patients missing at least 
one appointment was higher than was found 
in a study on missed appointments during 
the first 6 months among HIV-infected 
patients attending an ART outpatient clinic 
at the same facility[12] (35% of 4 476 patients 
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Fig. 1. Kaplan-Meier survival function: time from initiation of RR-TB treatment until first monthly 
appointment missed.
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Fig. 2. Kaplan-Meier survival function: time from treatment initiation until first missed appointment 
by treatment status at censoring.
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Fig. 3. Kaplan-Meier survival function: time from initiation of RR-TB treatment until first monthly 
appointment missed, by referring site type (outpatient or inpatient facility).
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missed one or more appointment). Con-
versely, the rates were conservative com-
pared with a more detailed analysis of 
missed treatment doses (treatment inter-
ruptions) during RR-TB treatment at a site 
in the Philippines,[7] where 93% of patients 
had at least one documented treatment 
interruption. The studies have in common 
that missing appointments was associated 
with poor outcomes.
This study was a retrospective review 
of medical records and therefore cannot 
determine either the reasons for the missed 
appointments or the direction of causality. 
The ‘treatment journey’ for patients on 
RR-TB treatment, especially those co- infected 
with HIV, can be a challenge for patients, and 
reasons for the treatment interruptions can 
be related to the patient or the healthcare 
system.[13] The proportion of RR-TB patients 
co-infected with HIV (86%) was much 
higher than the average for drug-susceptible 
TB patients in SA (61%). [1] The study also 
found a high degree of immunosuppression 
among RR-TB patients co-infected with 
HIV (median CD4 count 85  cells/µL, IQR 
26 - 195). This is of concern, as low CD4 
counts are a strong predictor of opportunistic 
infections and mortality among HIV-infected 
patients. Furthermore, the finding that a high 
proportion of HIV-infected patients (39.2%) 
were not on ART at the time of RR-TB 
treatment initiation confirms that they were 
not initiated on effective treatment for their 
HIV. The high risk of missed appointments 
among HIV-positive patients with a CD4 
count of ≤100  cells/µL (aHR 4.25, 95% 
CI  1.49 - 12.18) and patients referred from 
inpatient care reported here (aHR 1.96, 
95% CI 1.18 - 3.25) may be a result of these 
patients being too sick to attend outpatient 
appointments, and loss from treatment may 
include unreported deaths.[14] The missed 
appointments may also be a result of the 
inpatients not having a previous connection 
to the clinic providing daily treatment; a study 
from the same site found that 23% of drug-
sensitive TB patients diagnosed at the hospital 
never linked to the primary healthcare clinic 
for TB treatment.[15] Overall, 59.8% of missed 
appointments occurred within the first 
3  months after RR-TB treatment initiation. 
Missed appointments occurred earlier among 
patients referred from inpatient care than 
among those referred from outpatient care, 
again suggesting that sicker patients are more 
prone to missed appointments. As has been 
found with ART,[14] provider- and patient-
centred support to reduce early loss from 
treatment should be targeted at the first 
months after initiation.
Our finding that patients aged 18 - 24 years 
were at a three times higher risk and patients 
aged 25 - 34 years at a two times higher risk 
of missing an appointment compared with 
patients aged 35 - 44 years (aHR 3.26, 95% 
CI 1.20 - 8.84) was similar to the findings of 
other studies investigating loss to follow-up 
among DR-TB patients in decentralised care. 
A  de centralised DR-TB site in Khayelitsha, 
Western Cape Province, SA, found that 
patients aged 13 - 25 years were at a three times 
increased risk of loss to follow-up (OR  3.0, 
95% CI 1.1 - 8.1). [4] It is critical to develop 
targeted and age-appropriate interventions 
for the young patient initiated on RR-TB 
treatment to reduce missed appointments and 
loss to follow-up.
Table 3. Cox proportional hazards, risk of missing one or more appointments, time-to-
event regression
Description
Unadjusted HR
(95% CI)
Adjusted HR*
(95% CI) 
HIV status
Negative Reference Reference
Positive, CD4 >100 cells/µL 1.37 (0.66 - 2.82) 2.94 (1.07 - 8.10)
Positive, CD4 <101 cells/µL 1.95 (0.95 - 4.01) 4.25 (1.49 - 12.18)
Referring site
Inpatient 1.53 (1.01 - 2.32) 1.96 (1.18 - 3.25)
TB symptoms
Any cough 0.84 (0.54 - 1.29) 0.72 (0.43 - 1.21)
Site of TB
Pulmonary TB 1.68 (0.78 - 3.64) 2.77 (1.04 - 7.34)
Resistance
MDR-TB 0.77 (0.46 - 1.28) 0.83 (0.44 - 1.58)
TB history
No prior TB 0.96 (0.62 - 1.48) 1.25 (0.74 - 2.11)
Weight
<55 kg 0.92 (0.60 - 1.41) 0.61 (0.36 - 1.02)
Smear microscopy
Positive 0.83 (0.53 - 1.30) 1.10 (0.62 - 1.94)
Gender
Male 0.84 (0.56 - 1.27) 0.82 (0.48 - 1.40)
Age (years)
18 - 24 1.41 (0.65 - 3.07) 3.26 (1.20 - 8.84)
25 - 34 1.93 (1.20 - 3.12) 1.94 (1.10 - 3.44)
35 - 44 Reference Reference
45 - 54 1.11 (0.58 - 2.12) 1.36 (0.63 - 2.93)
≥55 0.66 (0.20 - 2.16) 1.22 (0.33 - 4.51)
Education
Primary Reference Reference
Secondary 0.77 (0.43 - 1.36) 0.59 (0.31 - 1.15)
Tertiary 0.29 (0.08 - 0.99) 0.28 (0.07 - 1.07)
Citizenship
Non-SA 1.25 (0.75 - 2.09) 1.04 (0.52 - 2.06)
Employment
Not employed 1.11 (0.73 - 1.68) 0.75 (0.45 - 1.27)
Children
Children ≤5 years 0.86 (0.56 - 1.32) 1.03 (0.63 - 1.71)
Bold font = statistically significant at p>0.05.
*Adjusted model includes all variables listed in the table.
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Study limitations
The study was limited to one site, so the results on missed 
appointments may not be generalisable to all outpatient RR-TB 
clinics. The study was retrospective and therefore limited to the 
data that were available. There was no information on patients 
who transferred out to other sites after their transfer. Despite these 
limitations, this study adds to the body of literature describing 
important demographic and clinical characteristics associated with 
missing appointments and loss to follow-up during the delivery of 
outpatient RR-TB treatment.
Conclusion
There are high rates of missed appointments among RR-TB patients 
in decentralised outpatient care. In order to achieve global targets for 
RR-TB treatment success, retention in treatment must be improved. 
The findings of this study highlight which patients need additional 
support in order to remain in care and prevent further transmission, 
morbidity and mortality. These interventions should look at both 
provider and patient reasons for loss to treatment, and may include 
patient reminders, tracing in the community, hospitalisation for 
patients in a poor clinical condition, dedicated patient transport, or 
other solutions.
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